Skip to main content
Log in

Construction of shRNA of fulminant hepatitis related gene mfgl2 and investigation of its biological effects in vitro

Virologica Sinica

Abstract

This study was designed to explore the RNA interference technique in inhibition of the expression of the mouse fibrinogen like protein 2 (mfgl2), which has been reported to be involved in the development a variety of diseases including fulminant viral hepatitis. A plasmid named p-mfgl2shRNA, complementary to the sequence of mfgl2 was constructed, while another short hairpin RNA (shRNA) which was a mutated form of the mfgl2shRNA sequences was used as a control. A plasmid named pEGFP-mfgl2 expressing the mfgl2-EGFP fusion protein was also constructed for the screening of the effect of p-mfgl2shRNA on mfgl2 expression. By cotransfection of p-mfgl2shRNA and pEGFP-mfgl2 or pcDNA3.1-mfgl2 expression construct into CHO cells or HeLa cells, the inhibition of mfgl2 expression by mfgl2shRNA was analyzed by direct observation through fluorescent microscopy, FACS, RT-PCR and immunohistochemistry staining. The experiments showed the significant inhibitory effect of p-mfgl2shRNA on mfgl2 expression at 48h post-transfection in both CHO and Hela cell lines with the inhibitory efficiency as high as 80.1%. The study demonstrated that the construct of p-mfgl2shRNA successfully interfered with the mfgl2 expression in vitro.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  1. Amarzguioui M, Prydz H. 2004. An algorithm for selection of functional siRNA sequences. Biochem Biophys Res Commun, 316: 1050–1058.

    Article  PubMed  CAS  Google Scholar 

  2. Arvelo M B, Cooper J T, Longo C, et al. 2002. A20 protects mice from D-galacto-samine/lipopolysaccharide acute toxic lethal hepatitis. Hepatology, 35: 535–543.

    Article  PubMed  CAS  Google Scholar 

  3. Ding J W, Ning Q, Liu M F, et al. 1997. Fulminant hepatic failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a novel fgl2 prothrombinase. J Virol, 71: 9223–9230.

    PubMed  CAS  Google Scholar 

  4. Hecht N, Pappo O, Shouval D, et al. 2001. Axelrod JH. Hyper-IL-6 gene therapy reverses fulminant hepatic failure. Mol Ther, 3: 683–687.

    Article  PubMed  CAS  Google Scholar 

  5. Huesken D, Lange J, Mickanin C, et al. 2005. Design of a genome-wide siRNA library using an artificial neural network. Nat Biotechnol, 23: 995–1001.

    Article  PubMed  CAS  Google Scholar 

  6. Khvorova A, Reynolds A, Jayasena S D. 2003. Functional siRNAs and miRNAs exhibit strand bias. Cell, 115: 209–216.

    Article  PubMed  CAS  Google Scholar 

  7. Kim D H, Behlke M A, Rose S D, et al. 2005. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol, 23: 222–226.

    Article  PubMed  CAS  Google Scholar 

  8. Levy G A, Liu M, Ding J, et al. 2000. Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis. Am J Pathol, 156: 1217.

    PubMed  CAS  Google Scholar 

  9. Li C, Fung L S, Chung S, et al. 1992. Monoclonal antiprothrombinase (3D4.3) prevents mortality from murine hepatitis virus (MHV-3) infection. J Exp Med, 176: 689–697.

    Article  PubMed  CAS  Google Scholar 

  10. Marsden P A, Ning Q, Fung L S, et al. 2003. The Fgl2/fibroleukin prothrombinase contributes to immunologically-mediated thrombosis in experimental and human viral hepatitis. J Clin Inves, 112: 58–66.

    Article  CAS  Google Scholar 

  11. Nakayama Y, Shimizu Y, Hirano K, et al. 2005. Sugiyama T CTLA-4Ig suppresses liver injury by inhibiting acquired immune responses in a mouse model of fulminant hepatitis. Hepatology, 42: 915–924.

    Article  PubMed  CAS  Google Scholar 

  12. Ning Q, Brown D, Parodo J, et al. 1998. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol, 160: 3487–3493.

    PubMed  CAS  Google Scholar 

  13. Reynolds A, Leake D, Boese Q, et al. 2004. Rational siRNA design for RNA interference. Nat Biotechnol, 22: 326–330.

    Article  PubMed  CAS  Google Scholar 

  14. Schwarz D S, Hutvagner G, Du T, et al. 2003. Asymmetry in the assembly of the RNAi enzyme complex. Cell, 115: 199–208.

    Article  PubMed  CAS  Google Scholar 

  15. Song E, Lee SK, Wang J, et al. 2003. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med, 8: 347–351.

    Article  Google Scholar 

  16. Ui-Tei K, Naito Y, Takahashi F, et al. 2004. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res, 32: 936–948.

    Article  PubMed  CAS  Google Scholar 

  17. Zhu C L, Sun Y, Luo X P, et al. 2006. Novel mfgl2 antisense plasmid inhibits mfgl2 expression and ameliorates MHV-3 induced fulminant hepatitis in Balb/cJ mice. Human Gene Therapy, 17: 589–600.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Qin Ning.

Additional information

Foundation items: National Natural Science Foundation of China ( No.30571643, No.30672380) and National Key Basic Research Program of China ( No. 2005CB2401, 2007CB512904)

These authors contributed equally.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xi, D., Wang, ZM., Gao, S. et al. Construction of shRNA of fulminant hepatitis related gene mfgl2 and investigation of its biological effects in vitro . Virol. Sin. 22, 366–373 (2007). https://doi.org/10.1007/s12250-007-0034-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12250-007-0034-z

CLC number

Key words

Navigation